Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | DGKA | P23743 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | PAM | P19021 | 2/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PRKCA | P17252 | 1/20 | 0.46 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416150 | 0.86 | LMNA (0.55) | MAPTDGKALMNAPAMDNM1 | |
| Isopropyl Alcohol SCHEMBL6139772 | 0.84 | MAPT (0.70) | MAPTDGKALMNAPAMDNM1 | |
| Isopropyl Alcohol SCHEMBL18584855 | 0.84 | MAPT (0.70) | MAPTDGKALMNAPAMDNM1 | |
| SCHEMBL8375548 | 0.84 | DGKA (0.75) | MAPTDGKALMNAPAMDNM1 | |
| Hexane SCHEMBL3151787 | 0.84 | DGKA (0.75) | MAPTDGKALMNAPAMDNM1 | |
| Hexane SCHEMBL2349171 | 0.84 | DGKA (0.75) | MAPTDGKALMNAPAMDNM1 | |
| SCHEMBL116995 | 0.84 | DGKA (0.75) | MAPTDGKALMNAPAMDNM1 | |
| SCHEMBL454 | 0.84 | DGKA (0.75) | MAPTDGKALMNAPAMDNM1 | |
| SCHEMBL5448566 | 0.84 | DGKA (0.75) | MAPTDGKALMNAPAMDNM1 | |
| SCHEMBL11527039 | 0.84 | DGKA (0.75) | MAPTDGKALMNAPAMDNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877750-B2 | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE B.V. (NL) | 2014-11-04 | — | — | US | disclosed |
| EP-1143977-B3 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE BV (NL) | 2012-10-24 | — | — | EP | disclosed |
| CN-1915981-B | 2-oxy-benzoxazinone derivatives for the treatment of obesity | NORGINE BV | 2011-09-28 | — | — | CN | disclosed |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | NORGINE B.V. (NL) | 2011-03-17 | — | — | US | disclosed |
| US-7858617-B2 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | NORGINE B.V. (NL) | 2010-12-28 | — | — | US | disclosed |
| US-7825113-B2 | An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis | NORGINE B.V. (NL) | 2010-11-02 | — | — | US | disclosed |
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | ALIZYME THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | US | disclosed |
| CN-1315813-C | 2-oxo-4H-3, 1-benzoxazin-4-ones for the treatment of obesity | ALIZYME THERAPEUTICS LTD (GB) | 2007-05-16 | — | — | CN | disclosed |
| CN-1915981-A | 2-oxy-benzoxazinone derivatives for the treatment of obesity | ALIZYME THERAPEUTICS LTD (GB) | 2007-02-21 | — | — | CN | disclosed |
| EP-1143977-B1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LTD (GB) | 2005-04-20 | — | — | EP | disclosed |
| US-20030195206-A1 | An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis | NORGINE B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
| US-6624161-B2 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | ALIZYME THERAPEUTICS LIMITED (GB) | 2003-09-23 | — | — | US | disclosed |
| US-20030027821-A1 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | NORGINE B.V. (NL) | 2003-02-06 | — | — | US | disclosed |
| WO-2000040247-A9 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LTD (GB) | 2002-10-24 | — | — | WO | disclosed |
| CN-1359378-A | 2-oxo-4H-3, 1-benzoxazine 4-ones for the treatment of obesity | ALIZYME THERAPEUTICS LTD (GB) | 2002-07-17 | — | — | CN | disclosed |
| EP-1144395-A1 | 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | Alizyme Therapeutics Limited (GB) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000040569-A1 | 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | ALIZYME THERAPEUTICS LIMITED (GB) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161301-A1 | 2-hexadecyloxy-6-methyl-4H-3,1-benzoxazin-4-one; inhibition of a lipase, esterase or phosphatase enzyme | LPL, LIPE, PNLIP | MAPT 4706/4885DGKA 1017/4885LMNA 2014/4885 |
| US-20110065697-A1 | 2-OXY-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY | CYP1B1, CYP4X1, ACOX1 | MAPT 4757/4885DGKA 2063/4885LMNA 1990/4885 |
| US-20030027821-A1 | Administering 2-oxy substituted benzoxazin-5-one derivative to a human or animal for the prevention or treatment of obesity or an obesity related disorder | CYP2F1, BBOX1, CES1 | MAPT 4061/4885DGKA 2985/4885LMNA 1592/4885 |
| US-20030195206-A1 | An enzyme inhibitors, enzyme is to catalyse the hydrolysis of an ester; treating hyperlipaemia, hyperglycaemia (type II diabetes), hypertension, cardiovascular disorders stroke, gastrointestinal disease; chemical intermediate synthesis | CES1, LIPC, PNLIP | MAPT 2799/4885DGKA 1063/4885LMNA 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.